Company Performance Metrics
ADispell is a biotech company dedicated to generating a fast return on investment for the discovery of drugs to treat and prevent memory loss conditions and disease.
ADispell research has revealed a novel mechanism that explains the onset of cognition loss and has discovered and validated lead compounds through in vivo experiments that interact
favorably with the mechanism. The Company has performed successful laboratory work and has a scientific plan to make the technology attractive to the pharmaceutical industry for licensing. ADispell operates a ‘license in - add value — license out’ model that will result in a much faster investment payback than other pharmaceutical projects. This payback structure is based on licensing fees, milestone payments, and royalties from product sales. The business has completed technology licensing from Cornell University and expects substantial income during the next three years, which will produce an attractive, rapid investment return. The experienced ADispell management team will take the promising technology, patented by Cornell, and advance it into a robust development of interest to one or more ‘big pharma’ companies, by proceeding through the middle, formative stages of the pharmaceutical drug development process, and then executing a license with a pharma development company. The licensing company is expected to develop at least one blockbuster drug for memory loss by completing the clinical trial stage of this process. This three-year ADispell project will proceed with investor and grant support in the first year and then with funding from pharmaceutical partners during years two and three. At least one significant payment event is expected at the end of three years as a pharma company licenses the technology for clinical trial and final development for sale. ADispell expects to stay involved with the project in an ongoing development role during this time. Longer term income (after 7 to 9 years) includes royalty payments based on the blockbuster drug sales with development milestone payments occurring in the time between these two payment periods. Additional treatments for other neurological diseases are very possible, resulting in parallel revenue streams. The project offers other product (and license) opportunities such as biomarkers to identify the onset or presence of AD (another unmet need) as well as the possibility to produce more than one drug compound for AD and dementia disorders.
